Archives
The big questions about Covid-19 booster shots – “From the why to the who, we still need a lot of answers about booster shots”.
17 Nov, 2021 | 08:48h | UTCThe big questions about Covid-19 booster shots – Vox
Commentary on Twitter
1/ Thoughtful piece by @voxdotcom's @germanrlopez on COVID vaccine boosters.
In good company with @ashishkjha @DrPaulOffit @MonicaGandhi9 @jenkatesdc.https://t.co/pOwZLkmJHn pic.twitter.com/ZAD7AOj0Vz
— Céline Gounder, MD, ScM, FIDSA 🇺🇦 (@celinegounder) November 12, 2021
Pfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries.
17 Nov, 2021 | 08:40h | UTCPfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries – HealthDay
See also:
Pfizer agrees to license generic versions of its COVID-19 pill — in some countries – NPR
Pfizer Will Allow Its Covid Pill to Be Made and Sold Cheaply in Poor Countries – The New York Times (a few articles per month are free)
AAN Guideline: Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease.
17 Nov, 2021 | 08:32h | UTCNews Release: AAN Issues Guideline for Treatment of Early Parkinson’s Disease – American Academy of Neurology
MSF responds to Pfizer and Medicines Patent Pool license for new Covid-19 treatment – “The deal, however, only covers 53 percent of the world’s population and excludes people in several upper-middle-income countries, leaving this promising medicine out of reach for millions”.
17 Nov, 2021 | 08:38h | UTC
Commentary on Twitter
Pfizer's deal w/ the Medicines Patent Pool for its COVID-19 treatment doesn't allow enough generic production & leaves this medicine out of reach for millions.
This is yet another restrictive voluntary license as cases continue to rise in many countries. https://t.co/WbVmUt9nrH
— Doctors w/o Borders (@MSF_USA) November 16, 2021
Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.
17 Nov, 2021 | 08:42h | UTCRelated:
Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
Characterizing long COVID: a living systematic review.
Long Covid – The illness narratives.
New guidelines to help doctors manage long COVID patients published.
M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)
Individual participant data meta-analysis of major randomized trials showed that treatment of hypertension with ACEIs or ARBs reduced the risk of new-onset type 2 diabetes compared to other drugs.
17 Nov, 2021 | 08:29h | UTCCommentaries:
Blood pressure drugs could prevent type 2 diabetes, study finds – The Guardian
Position Statement: Preoperative Care for Cataract Surgery – “In spite of evidence debunking the utility of testing before cataract surgery, studies suggest that medical testing and the use of medical consultations before cataract surgery continue to increase”.
17 Nov, 2021 | 08:33h | UTC
Commentary on Twitter
Nicely written position paper on preop care for cataract surgery. Addresses the most frequent questions (although actual study data is limited). Basically no tests, continue meds, and proceed in most cases unless recent MI,PCI,VTE,CVA,DKA, or HTN urgency. https://t.co/PLHm1LjhZg
— Steven Cohn, MD (@preopconsult) November 16, 2021
Randomized, crossover clinical trial: In patients with heart failure with preserved ejection fraction and chronotropic incompetence, betablocker withdrawal improved maximal functional capacity.
17 Nov, 2021 | 08:27h | UTCCommentary: Peak VO2 Improved After Beta-Blocker Withdrawal in Some HFpEF Patients: Beta-blockers may not benefit HFpEF patients with chronotropic incompetence – MedPage Today (free registration required)
Nursing care for oncologic patients undergoing surgery using an enhanced recovery approach.
17 Nov, 2021 | 08:22h | UTCOncologic Surgical Care Using an Enhanced Recovery Approach – AACN Advanced Critical Care
News release: Enhanced Recovery Approach Changes Care for Surgical Oncology Patients – American Association of Critical-Care Nurses
Related: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Phase 2 RCT: Once-weekly cagrilintide is effective for weight management in people with overweight and obesity.
17 Nov, 2021 | 08:23h | UTCOnce-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial – The Lancet (link to abstract – $ for full-text)
RCT: Adjustable intragastric balloon resulted in significant weight loss at 32 weeks, but intolerance caused early removal of the device in 17% of patients, and device-related serious adverse events were observed in 4% of patients.
17 Nov, 2021 | 08:26h | UTCAdjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
In this trial, when an adjustable intragastric balloon was combined with lifestyle modification in adults with obesity, significant weight loss was achieved and maintained for 6 months following device removal. https://t.co/jg7z5ldeC7 #GITwitter pic.twitter.com/Pi9PVAeWzo
— The Lancet (@TheLancet) November 16, 2021
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.
17 Nov, 2021 | 08:19h | UTC
Commentary on Twitter
PRS scores are moving closer to widespread clinical use.
In our latest Perspective, a panel of experts in genetics, law, and ethics discuss recent advances and potential benefits, risks, and gaps. @ICDAbio @cristenw @minouye271 @umichCVC @Cambridge_Unihttps://t.co/ZBvBGy4XPr— Nature Medicine (@NatureMedicine) November 16, 2021
Long-term follow up of randomized trials found that children who were given nutrient or supplement enriched formula milk as babies didn’t have higher academic performances as adolescents.
17 Nov, 2021 | 08:14h | UTCNews release: Study finds no benefit of enriched formula milks on later academic performance – British Medical Journal
Editorial: Enriched formula milks and academic performance in later childhood – The BMJ
Commentary on Twitter
https://twitter.com/bmj_company/status/1458691047933026307
A billion-dollar donation: estimating the cost of researchers’ time spent on peer review.
17 Nov, 2021 | 08:16h | UTCRelated:
The $450 question: Should journals pay peer reviewers?
Opinion: Peer reviewers—time for mass rebellion?
5 things we learned about peer review in 2020
Editorial: Evaluation and Peer Review During a Pandemic
Commentary on Twitter
Peer reviewers worked over 100 million hours in 2020, estimated value $1.5 billion https://t.co/tY9klsLedU Feat @ceptional pic.twitter.com/kNn1Blovxg
— Neuroskeptic 🇺🇦 (@Neuro_Skeptic) November 16, 2021
Real-world ethics in palliative care: A systematic review of the ethical challenges reported by specialist palliative care practitioners in their clinical practice.
17 Nov, 2021 | 08:18h | UTC
Commentary on Twitter
The range of ethical challenges faced by specialist palliative care practitioners exceeds the breadth of those detailed in palliative care textbooks and ethics resources. #hpm #hapc https://t.co/pvwkYrJmIo pic.twitter.com/qb5803oQg1
— Palliative Medicine (@PalliativeMedJ) March 3, 2021
Drug-induced orthostatic hypotension: A systematic review and meta-analysis of randomized controlled trials.
17 Nov, 2021 | 08:12h | UTC
RCT: Intravenous immunoglobulins do not improve outcomes in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome.
16 Nov, 2021 | 08:48h | UTC
Commentary on Twitter
NEW Research—In pts w/ #COVID19 who received IMV for mod-to-sev #ARDS, intravenous immunoglobulins did not improve clinical outcomes at day 28
Phase 3 ICAR trial from Prof Tarek Sharshar & colleagues https://t.co/TBWxngXIPT pic.twitter.com/W2dNBaM1o1
— The Lancet Respiratory Medicine (@LancetRespirMed) November 12, 2021
IDSA/ASM Consensus Review Document: Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping.
16 Nov, 2021 | 08:50h | UTCNews Release: New review article outlines potential of SARS-CoV-2 genetic sequencing in patient care – American Society for Microbiology
Review: Vaccine-induced immune thrombotic thrombocytopenia.
16 Nov, 2021 | 08:46h | UTCVaccine-induced immune thrombotic thrombocytopenia – The Lancet Haematology
Related:
Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Commentary on Twitter
NEW Viewpoint by @Erik_Klok_MD, @MPaiMD, Menno Huisman & @ProfMakris discussing the epidemiology, pathophysiology, and optimal diagnostic and therapeutic management of vaccine-induced immune thrombotic thrombocytopenia #VITT #COVID19Vaccine https://t.co/FI4NynwzEn pic.twitter.com/9PbjaioA2T
— The Lancet Haematology (@TheLancetHaem) November 12, 2021
Covid: Austria introduces lockdown for unvaccinated.
16 Nov, 2021 | 08:43h | UTCCovid: Austria introduces lockdown for unvaccinated – BBC
See also: Austria orders nationwide lockdown for the unvaccinated – Associated Press
Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding.
16 Nov, 2021 | 08:42h | UTC
Commentary on Twitter
Seventy countries have yet to vaccinate 10% of their populations for covid-19. What is holding up the process?
Includes a #BMJInfographic that shows whether countries producing vaccines are able to vaccinate more of their populationshttps://t.co/9Z9BtzJKR9 pic.twitter.com/zfUfSgZQtC
— The BMJ (@bmj_latest) November 2, 2021
Pfizer’s pill is the latest COVID treatment to show promise. Here are some more.
16 Nov, 2021 | 08:41h | UTCPfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation
Related:
The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.
Merck to allow other nations to produce new COVID-19 antiviral.
Video: Merck’s Covid pill could transform treatment. Here’s how it works.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
What we know — and don’t know — about Merck’s new Covid-19 pill.
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used.
16 Nov, 2021 | 08:39h | UTCRelated:
The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.
Merck to allow other nations to produce new COVID-19 antiviral.
Video: Merck’s Covid pill could transform treatment. Here’s how it works.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
What we know — and don’t know — about Merck’s new Covid-19 pill.
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
New WHO report maps barriers to insulin availability and suggests actions to promote universal access – “100 years after its discovery, insulin still out of reach for many living with diabetes”.
16 Nov, 2021 | 08:34h | UTCReport: Keeping the 100-year-old promise: making insulin access universal – World Health Organization
Commentary: Half the People Living with Diabetes Can’t Afford Insulin, WHO Report Shows – Health Policy Watch
Related:
Editorial | Insulin for all: a hope yet to be realized.
One hundred years of insulin therapy.
Commentary on Twitter (thread – click for more)
https://twitter.com/WHO/status/1459194472022122500
2021 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
16 Nov, 2021 | 08:37h | UTC2021 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Neonatal Life Support; Education, Implementation, and Teams; First Aid Task Forces; and the COVID-19 Working Group – Circulation (for an HTML version click here)
Top Things to Know: International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations (CoSTR) – American Heart Association